*.- Los Resultados con Zepsyre Ovario serán presentados en el Congreso ASCO.
*.- Zepsyre combinado con Doxorubicin para el Tratamiento de Cáncer de Pulmón de Celulas Pequeñas está acabando de reclutar los Pacientes de la Fase III .
*.- Zepsyre "" en Solitario "" podria también ser efectivo para el Tratamiento de Cancer de Pulmón de Células Pequeñas ... Ojo porque esto es muy muy importante ya que si combinado con Doxorubicin se le Preveen ventas de 600 millones anuales ... Imaginemonos si pudiera ir en solitario !!!.
Se están centrando en el Zepsyre Pulmón y Endometrio con todos los datos actuales ... así como el historial del yondelis con J&J y Taiho y su comercialización en Sarcomas y Ovario .
PharmaMar is a global biopharmaceutical company, focused on oncology and committed to research and development which takes inspiration from the sea to discover molecules with antitumor activity. It is an integrated company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it a world leader in the discovery of antitumor drugs of marine origin.
With subsidiaries in Europe and the United States, PharmaMar has an important pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid and hematological cancers, lurbinectedin (PM1183), plitidepsin, and PM184.
PharmaMar fully owns other companies: GENOMICA, Spain’s leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel.
